Morning Market Losers

shares fell 23.92 percent to $8.30 after the company reported results from its Phase 2a clinical trial evaluating tenapanor in chronic kidney disease patients.

shares tumbled 22.58 percent to $1.01. Anadigics reported a Q1 adjusted loss of $0.04 per share on revenue of $18.4 million.

shares dipped 22.07 percent to $16.14 after the company reported weaker-than-expected Q1 results and issued a weak FY15 guidance.

shares slipped 19.29 percent to $9.54 after the company reported downbeat Q2 revenue and issued a weak revenue outlook. The company also named Brian Swartz as chief financial officer.

shares dipped 16.15 percent to $9.97 after the company reported weaker-than-expected Q1 results and issued a downbeat Q2 forecast.

shares dropped 12.85 percent to $21.90 after the company reported a wider-than-expected Q1 loss.

shares fell 11.23 percent to $10.75. Enphase reported Q1 adjusted loss of $0.07 per share on revenue of $86.7 million.

declined 10.27 percent to $151.24. Alexion Pharmaceuticals announced its plans to acquire

for $8.4 billion and raised share repurchase authorization to $1 billion.

shares fell 8.12 percent to $9.51 after the company reported downbeat Q1 results and issued a weak revenue outlook.

shares dropped 3.87 percent to $6.57. Groupon reported better-than-expected earnings for the first quarter, but the company's sales missed analysts' estimates.